These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18632433)

  • 1. Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor.
    Dogan M; Demirkazik A
    Support Cancer Ther; 2005 Oct; 3(1):28-34. PubMed ID: 18632433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS).
    Posch F; Thaler J; Zlabinger GJ; Königsbrügge O; Koder S; Zielinski C; Pabinger I; Ay C
    Clin Cancer Res; 2016 Jan; 22(1):200-6. PubMed ID: 26302981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer.
    Rickles FR; Shoji M; Abe K
    Int J Hematol; 2001 Feb; 73(2):145-50. PubMed ID: 11372724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The link between cancer and venous thromboembolism: a review.
    Kessler CM
    Am J Clin Oncol; 2009 Aug; 32(4 Suppl):S3-7. PubMed ID: 19654481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors.
    Tripodi A; Ammollo CT; Semeraro F; Colucci M; Malchiodi E; Verrua E; Ferrante E; Arnaldi G; Trementino L; Padovan L; Chantarangkul V; Peyvandi F; Mantovani G
    Endocrine; 2017 May; 56(2):298-307. PubMed ID: 27448294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
    Syrigos K; Grapsa D; Sangare R; Evmorfiadis I; Larsen AK; Van Dreden P; Boura P; Charpidou A; Kotteas E; Sergentanis TN; Elalamy I; Falanga A; Gerotziafas GT
    Oncologist; 2018 Nov; 23(11):1372-1381. PubMed ID: 30104289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for venous thromboembolism in children.
    Gerotziafas GT
    Int Angiol; 2004 Sep; 23(3):195-205. PubMed ID: 15765033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-associated venous thromboembolism: Burden, mechanisms, and management.
    Ay C; Pabinger I; Cohen AT
    Thromb Haemost; 2017 Jan; 117(2):219-230. PubMed ID: 27882374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism.
    Goldenberg N; Kahn SR; Solymoss S
    J Clin Oncol; 2003 Nov; 21(22):4194-9. PubMed ID: 14615447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of current and emerging antithrombotics in thrombosis and cancer.
    Mousa SA
    Drugs Today (Barc); 2006 May; 42(5):331-50. PubMed ID: 16801996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thromboembolism syndrome in gynecological cancer.
    Wang X; Fu S; Freedman RS; Kavanagh JJ
    Int J Gynecol Cancer; 2006; 16 Suppl 1():458-71. PubMed ID: 16515646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology.
    Winter PC
    Hematol Oncol; 2006 Sep; 24(3):126-33. PubMed ID: 16783843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis.
    Goertz L; Schneider SW; Desch A; Mayer FT; Koett J; Nowak K; Karampinis I; Bohlmann MK; Umansky V; Bauer AT
    Oncotarget; 2016 Oct; 7(42):68527-68545. PubMed ID: 27602496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A shortened activated partial thromboplastin time predicts the risk of catheter-associated venous thrombosis in cancer patients.
    Senthil M; Chaudhary P; Smith DD; Ventura PE; Frankel PH; Pullarkat V; Trisal V
    Thromb Res; 2014 Jul; 134(1):165-8. PubMed ID: 24830901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk of venous thromboembolism in cancer patients: Reality, actuality and perspectives].
    Gerotziafas GT; Elalamy I
    Bull Cancer; 2016 Sep; 103(9):764-75. PubMed ID: 27481723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Inflammation in Venous Thromboembolism.
    Branchford BR; Carpenter SL
    Front Pediatr; 2018; 6():142. PubMed ID: 29876337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue factor and fibrin in tumor angiogenesis.
    Fernandez PM; Patierno SR; Rickles FR
    Semin Thromb Hemost; 2004 Feb; 30(1):31-44. PubMed ID: 15034796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer and thromboembolic disease: pathogenic mechanisms.
    Lee AY
    Cancer Treat Rev; 2002 Jun; 28(3):137-40. PubMed ID: 12234564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.